We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+16.5%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.25B
AUM Growth
+$394M
Cap. Flow
+$465M
Cap. Flow %
20.62%
Top 10 Hldgs %
64.72%
Holding
86
New
21
Increased
10
Reduced
4
Closed
15

Top Buys

Rank Stock Value
1
NUVB icon
Nuvation Bio
NUVB
+$148M
2
ANAB icon
AnaptysBio
ANAB
+$99.1M
3
KURA icon
Kura Oncology
KURA
+$60.7M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$39.7M
5
DSGN icon
Design Therapeutics
DSGN
+$38.4M

Top Sells

Rank Stock Value
1
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
+$44.3M
2
GERN icon
Geron
GERN
+$30.1M
3
VINC
Vincerx Pharma, Inc. Common Stock
VINC
+$10M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$9.77M
5
CMAX
CareMax, Inc. Class A Common Stock
CMAX
+$7.51M

Sector Composition

Rank Sector Weight
1 Healthcare 98.25%
2 Miscellaneous 1.13%
3 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
1
Prothena Corp
PRTA
$479M
$277M 12.29%
11,034,280
+1,607,640
+17% +$30.2M
XNCR icon
2
Xencor
XNCR
$1.94B
$211M 9.36%
4,900,306
+353,234
+8% +$16.7M
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$190M 8.42%
2,999,315
+159,431
+6% +$7.32M
ANAB icon
4
AnaptysBio
ANAB
$1.67B
$154M 6.84%
7,151,624
+3,928,300
+122% +$99.1M
NUVB icon
5
Nuvation Bio
NUVB
$2.34B
$138M 6.14%
+13,247,017
New +$148M
RLAY icon
6
Relay Therapeutics
RLAY
$4.11B
$119M 5.26%
3,429,363
+228,714
+7% +$9.93M
SPRY icon
7
ARS Pharmaceuticals
SPRY
$586M
$111M 4.9%
2,533,635
– –
KURA icon
8
Kura Oncology
KURA
$1.13B
$104M 4.63%
3,692,637
+1,919,600
+108% +$60.7M
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$79.5M 3.53%
464,298
– –
ORIC icon
10
Oric Pharmaceuticals
ORIC
$1.37B
$75.8M 3.36%
3,092,218
– –
STTK icon
11
Shattuck Labs
STTK
$707M
$71.9M 3.19%
2,458,259
+1,405
+0.1% +$59K
NRIX icon
12
Nurix Therapeutics
NRIX
$2.72B
$62.8M 2.78%
2,019,019
+475,000
+31% +$18M
RCUS icon
13
Arcus Biosciences
RCUS
$3.72B
$61.7M 2.73%
2,195,892
– –
SLDB icon
14
Solid Biosciences
SLDB
$1.05B
$50.9M 2.26%
613,513
+81,666
+15% +$9.04M
RNAM
15
DELISTED
Avidity Biosciences
RNAM
$45.9M 2.04%
2,103,950
– –
EWTX icon
16
Edgewise Therapeutics
EWTX
$4.64B
$39.8M 1.76%
+1,224,175
New +$39.7M
NGNE icon
17
Neurogene
NGNE
$732M
$38.4M 1.7%
156,135
– –
BCEL
18
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$37.2M 1.65%
2,426,685
– –
DSGN icon
19
Design Therapeutics
DSGN
$946M
$34M 1.51%
+1,137,940
New +$38.4M
GRTS
20
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$32.3M 1.43%
3,421,287
– –
ACIU icon
21
AC Immune
ACIU
$263M
$27.8M 1.23%
3,648,163
+1,237,923
+51% +$8.84M
AKUS
22
DELISTED
Akouos Inc
AKUS
$27.4M 1.22%
1,975,984
– –
OVID icon
23
Ovid Therapeutics
OVID
$547M
$24.4M 1.08%
+6,082,200
New +$20.2M
ARVN icon
24
Arvinas
ARVN
$600M
$21.1M 0.93%
+318,704
New +$24.4M
KDNY
25
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$19.4M 0.86%
1,250,001
– –
1
2 3 4

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q1 2021 Portfolio in Review

As of Q1 2021, EcoR1 Capital held 86 positions worth $2.25B, up 21% from $1.86B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

EcoR1 Capital deployed $465M of net new capital in Q1 2021, opening 21 new positions and adding to 10 existing holdings. Its largest new stake was Nuvation Bio: 13,247,017 shares worth $138M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Applied Molecular Transport Inc. Common Stock, an estimated $44.3M trimmed.

  • EcoR1 Capital's largest Q1 2021 buy was Nuvation Bio: 13,247,017 shares worth $138M.
  • EcoR1 Capital added most to AnaptysBio in Q1 2021, an estimated $99.1M increase.
  • EcoR1 Capital's biggest Q1 2021 reduction was Applied Molecular Transport Inc. Common Stock, cutting an estimated $44.3M.
  • EcoR1 Capital fully exited Geron in Q1 2021, selling an estimated $30.1M.
  • EcoR1 Capital's ten largest holdings make up 65% of its $2.25B portfolio in Q1 2021.
  • EcoR1 Capital opened 21 new positions and closed 15 in Q1 2021.
  • EcoR1 Capital's portfolio value rose 21% quarter-over-quarter to $2.25B.

Based on EcoR1 Capital's 13F filing for Q1 2021, filed 17 May 2021.